Deal volumes and values are tracking above the first half of 2025, driven by Boston Scientific’s Penumbra buyout and ...

Star51 Capital announced today that it completed the first close of its inaugural fund for early- and growth-stage medtech ...

EY released its Pulse of the MedTech Industry Report 2025 this week, featuring insights on M&A and other trends across the medtech landscape this year. “This is EY's 19th year publishing the report ...

MedtechWOMEN to convene industry leaders at MedtechVISION 2026 capital, AI and geopolitics reshape medtech —Nationally recognized health ...

Johnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. In the ever-evolving landscape of the MedTech industry, one thing ...

A new report from JP Morgan, in partnership with Dealforma, has proven that medtech mergers and IPOs are alive and well in 2025. The Q3 ‘25 Biopharma & Medtech Licensing and Venture Report, published ...

MedTech Europe has voiced broad support for proposed changes to the In Vitro Diagnostic Regulation (IVDR), welcoming many proposals and pushing for the strengthening of some revisions.

While most venture capital fled early-stage medical devices, Catalyst Health Ventures stayed, and built a disciplined model that keeps producing exits.

As 2026 begins, India’s MedTech sector reflects on a year of consolidation, resilience, and strategic progress. The past year has strengthened a more competitive, innovation-led ecosystem, with access ...

Star51 Capital, a venture capital investment platform designed to bridge the gap between innovation and acquisition, today announced the first close of its inaugural fund. The fund's first closing was ...